AKT1 and breast cancer: Combinatorial treatment targeting OXPHOS with the thioredoxin reductase (TrxR) inhibitor D9 and the Akt inhibitor MK-2206 selectively eradicated breast cancer cells without affecting bone marrow stromal cells.